These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26538507)

  • 1. Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project.
    Delgado-Valverde M; Torres E; Valiente-Mendez A; Almirante B; Gómez-Zorrilla S; Borrell N; Corzo JE; Gurgui M; Almela M; García-Álvarez L; Fontecoba-Sánchez MC; Martínez-Martínez L; Cantón R; Praena J; Causse M; Gutiérrez-Gutiérrez B; Roberts JA; Farkas A; Pascual Á; Rodríguez-Baño J;
    J Antimicrob Chemother; 2016 Feb; 71(2):521-30. PubMed ID: 26538507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia.
    Marcos M; Iñurrieta A; Soriano A; Martínez JA; Almela M; Marco F; Mensa J
    J Antimicrob Chemother; 2008 Aug; 62(2):397-403. PubMed ID: 18420813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae.
    Delgado-Valverde M; Valiente-Mendez A; Torres E; Almirante B; Gómez-Zorrilla S; Borrell N; Aller-García AI; Gurgui M; Almela M; Sanz M; Bou G; Martínez-Martínez L; Cantón R; Antonio Lepe J; Causse M; Gutiérrez-Gutiérrez B; Pascual Á; Rodríguez-Baño J;
    J Antimicrob Chemother; 2017 May; 72(5):1478-1487. PubMed ID: 28093484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
    PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam.
    Gentry CA; Williams RJ
    Int J Antimicrob Agents; 2017 Mar; 49(3):333-338. PubMed ID: 28108367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
    Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
    Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
    Sugimoto N; Yamagishi Y; Mikamo H
    J Infect Chemother; 2017 Jan; 23(1):65-67. PubMed ID: 27693013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicentre in vitro evaluation of piperacillin/tazobactam in Germany.
    Grimm H
    Eur J Surg Suppl; 1994; (573):25-9. PubMed ID: 7524792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raoultella planticola bacteraemia.
    Hu AY; Leslie KA; Baskette J; Elsayed S
    J Med Microbiol; 2012 Oct; 61(Pt 10):1488-1489. PubMed ID: 22820690
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
    Peterson LR
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
    Retamar P; López-Cerero L; Muniain MA; Pascual Á; Rodríguez-Baño J;
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3402-4. PubMed ID: 23612190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
    DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Usefulness of piperacillin/tazobactam resistance as a predictor of OXA-48 carbapenemase in Enterobacteriaceae].
    Grados M; Fernández S; Lara N; Alós JI
    Rev Esp Quimioter; 2017 Aug; 30(4):299-300. PubMed ID: 28541011
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
    Gesser RM; McCarroll K; Teppler H; Woods GL
    J Antimicrob Chemother; 2003 May; 51(5):1253-60. PubMed ID: 12697633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms.
    McKamey L; Venugopalan V; Cherabuddi K; Borgert S; Voils S; Shah K; Klinker KP
    Int J Antimicrob Agents; 2018 Nov; 52(5):719-723. PubMed ID: 30125680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
    Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
    Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.